Intraarterial chemioterapy in retinoblastoma treatment - 4 years experience

Congress:

ECR 2020

Poster Number:

C-02090

Type:

Scientific Exhibit

Keywords:

Not applicable, Experimental, Education and training, Technical aspects, Chemotherapy, Arterial access, Percutaneous, Catheter arteriography, Oncology, Interventional vascular, Eyes, Interventional Radiology

Authors:

P. A. Rago¹, J. Bartuszek², E. Jurkiewicz¹, U. H. Pasik¹, J. Debska¹; ¹Warsaw/PL, ²Warszawa/PL

DOI:

10.26044/ecr2020/C-02090

DOI-Link:

https://dx.doi.org/10.26044/ecr2020/C-02090

Fig. 6: MRI results of IAC - complete remission

Fig. 7: Results of IAC - inactive calcified RBL

Fig. 8: Results of IAC (MRI) - inactive calcified RBL

Fig. 4: O.A. angiogram before IAC

Results

Between 2015 and 2019 we have performed over 200 IAC procedures with over 95% technical success in the whole period and 100% technical success in the last year.

Recurrence rate is under 30 %, mostly in one eye in children with bilateral retinoblastoma (children with modyfied chemotherapy). Less that 15% need next IAC session apart from crioteraphy and laser therapy. We observed constant number of recurrence in bilateral retinoblastoma group and lower number of recurrent tumors in unilateral retinoblastoma group with development of meningeal media approach and desist of the balloon technique.

Predictable side effects of IAC include swelling of the eyelid, bleeding into the eye, eye muscle dysfunctions, drooping of the upper eyelid. In some cases we noted drop in blood pressure and bronchospasm during the procedure, a mild, self withdrawing anaesthesia complication. Under 5% suffer from complications of the arterial access including: haematoma or elongated bleeding. During 4 years we encountered two TIA incidents with no long-term effect and two incidents of skin necrosis.